Efficacy of Atorvastatin in Chronic Subdural Haematoma

• Status: Recruiting
• Trial end date: 2021-10-31
• Target enrollment: 0
• Participant gender: All

Summary

This prospective, double-blind, randomized, placebo-controlled study aims to evaluate the efficacy and safety of atorvastatin in patients with chronic subdural haematoma. The degree of disability or dependence in daily activities, as well as surgical intervention or recurrence, of the treatment and control groups will be compared.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese University of Hong Kong
• Treatments: Atorvastatin

Criteria

Inclusion Criteria:

1. Age greater than or equal to 18 years old;

2. Evidence of supratentorial chronic subdural haematoma (unilateral or bilateral) by Computed Tomography (CT);

3. Patients are joining the trial voluntarily with consent form signed.

Exclusion Criteria:

1. Allergy to atorvastatin or other statins;

2. Deranged liver function;

3. Patients who are already on long term steroid for other condition(s);

4. Patients who are already on statin for other condition(s);

5. Presence of cerebrospinal fluid diversion device (e.g. ventriculo-peritoneal shunt);

6. Pregnant or on breast feeding;

7. Hematoma is secondary to tumour or haematological disorders;

8. Patients taking angiotensin converting enzyme (ACE) inhibitor.